ELISA/assay

Omalizumab (XOLAIR) ELISA

KBI1021

1 x 96 well

Omalizumab (XOLAIR) ELISA

Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria.Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Omalizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Omalizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Omalizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Omalizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

ELISA

Assay Kits

Therapeutic Drug Monitoring

1 x 96 well

Omalizumab

Omalizumab

<2.5 ng/mL

2.5-160 ng/ml

100 uL

Serum, Plasma, Cell Culture Supernatants

2.5 hours

RUO

wet

2-8C